Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Fig. 1

Efficacy of JX-594 combined with low-dose cyclophosphamide (A, C, E) and of low-dose cyclophosphamide (B, D, F) in patients advanced sarcomas. A and B Waterfall plot of the maximum change in tumor size in 12 and 4 patients with sarcomas and eligible for efficacy analysis in arms 1 (A) and 2 (B), respectively. C and D Representative spider plot illustrating changes from baseline in tumor burden according to RECIST criteria in patients from arm 1 (C) and arm 2 (D). E and F Kaplan–Meier curves associated with PFS (E) and OS (F) in arm 1 (red line) and arm 2 (blue line) (n = 16)

Back to article page